OncoDNA's OncoSelect

Belgian biotech firm OncoDNA has launched OncoSelect, an assay for circulating tumor DNA in blood samples from non-small cell lung cancer, colon cancer, or breast cancer (ER+ or HER2+) patients. OncoSelect assays for more than 100 mutations of resistance and sensitivity to targeted therapies. To monitor progression of cancer, the test should ideally be performed midway through treatment and two weeks after the last does, the company said. Turnaround time from receipt of sample to issuance of a full report to the treating oncologist is seven working days.